CSV November 24, 2022 through November 25, 2024 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DILUTED	*USP Reference*	*USP38–NF33*	3973	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second*	Line 2 of USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ISOSORBIDE MONONITRATE	*standards <11>*						*Supplement to USP39–NF34*	Diluted Isosorbide Mononitrate Related Compound A RS: Change 1,4:3,5-Dianhydro-D-glucitol 2-nitrate. to: 1,4:3,6-Dianhydro-D-glucitol 2-nitrate.
CEFDINIR FOR ORAL SUSPENSION	PERFORMANCE TESTS/ *Dissolution <711>*	*First Supplement to USP38–NF33*	7357	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 5 of *Analysis*: Change Result = $(A_U/A_S) \times C_S \times d \times V \times D \times (1/L) \times 100$ to: Result = $(A_U/A_S) \times C_S \times (d/W_U) \times V \times D \times (1/L) \times 100$ AND Add to the variable definition list W_U = weight of reconstituted Cefdinir for Oral

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CORTICOTROPIN INJECTION	ASSAY/ *Procedure*	*Second Supplement to USP38–NF33*	8059	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Suspension taken (mg) Line 7 of *Replication*: Change (see <111>, *Confidence Intervals for Individual Assays*). to: (see <111>, *The Confidence Interval and Limits of Potency*).
MANNITOL INJECTION	*Specific rotation <781>*	*Second Supplement to USP38–NF33*	Online	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 1: Change Transfer an accurately measured volume of Injection, equivalent to about 1 g of mannitol as determined by the *Assay*, to a 100-mL volumetric flask:it meets the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								requirements of the test for *Specific rotation* under *Mannitol*. to: +137° to +145°.Transfer an accurately measured volume of Injection, equivalent to about 1 g of mannitol as determined by the *Assay*, to a 100-mL volumetric flask. Add 40 mL of a 1-in-10 ammonium molybdate solution, previously filtered if necessary. Add 20 mL of 1 N sulfuric acid, and dilute with water to volume.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ATOMIC ABSORPTION SPECTROSCOPY	VALIDATION AND VERIFICATION/ *Precision/Intermediate Precision*	*USP38–NF33*	649	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 3: Change As a minimum, the analytical procedure should be assessed by performing the repeatability test in any of the conditions previously mentioned (totaling 12 measurements). to: As a minimum, the analytical procedure should be assessed by performing the repeatability test in any combination of at least two of the conditions previously mentioned (totaling 12 measurements).
OLOPATADINE	IM	*USP38–NF33*	4625	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second*	Add

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
HYDROCHLORIDE OPHTHALMIC SOLUTION	PURITIES/*Limit of Late Eluting Impurities*						*Supplement to USP39–NF34*	[Note–Protect solutions from light.]
MILK THISTLE	COMPOSITION /*Content of Silymarin*	*Second Supplement to USP38–NF33*	7878	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 3 of *Sample stock solution*: Change Transfer the thimble to a con tinuous-extraction apparatus fitted with a 250-mL round-bottom flask containing 150 mL of hexane, and heat the flask on a heating mantle for 4 h. After the extraction, detach the round-bottom flask from the extraction apparatus, and discard the hexane. Dry the extraction

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								thimble to remove residual hexane, to: Transfer the thimble to a con tinuous-extraction apparatus fitted with a 250-mL round-bottom flask containing 150 mL of solvent hexane, and heat the flask on a heating mantle for 4 h. After the extraction, detach the round-bottom flask from the extraction apparatus, and discard the solvent hexane. Dry the extraction thimble to remove residual solvent hexane,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LOPINAVIR AND RITONAVIR ORAL SOLUTION	IMPURITIES/*Organic Impurities*	*Second Supplement to USP38–NF33*	8139	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Row 17 of Column 3 of *Table 2*: Change 0.2 to: 0.2[p] AND Add footnote [p]Disregard any peak less than 0.01%.
ISOSORBIDE MONONITRATE TABLETS	*USP Reference standards <11>*	*USP38–NF33*	3974	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 2 of USP Diluted Isosorbide Mononitrate Related Compound A RS: Change 1,4:3,5-Dianhydro-D-glucitol 2-nitrate. to: 1,4:3,6-Dianhydro-D-glucitol 2-nitrate.
METAXALONE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*First Supplement to USP38–NF33*	7432	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 2 of *Buffer, Mobile phase, Chromatographic system,* and *System*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								suitability: Change Proceed as directed in the *Assay*. to: Proceed as directed in the *Assay*, except use 270 nm for analysis. AND Line 10 of *Analysis*: Change *V* = volume of the *Medium*, 750 mL to: *V* = volume of the *Medium*, 900 mL
CORTICOTROPIN FOR INJECTION	ASSAY/ *Procedure*	*Second Supplement to USP38–NF33*	8061	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 7 of *Replication*: Change (see <111>, *Confidence Intervals for Individual Assays*). to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(see <111>, *The Confidence Interval and Limits of Potency*).
PACKAGING AND STORAGE REQUIREMENTS	GENERAL DEFINITIONS	*USP38–NF33*	447	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 1 of *Single-Dose* (see also *Injections <1>, Containers for Injections*): Change A single-unit package for an article intended for parenteral administration. Examples of single-dose containers include prefilled syringes, cartridges, fusion-sealed containers, and closure-sealed containers when so labeled. to: A single-unit package for an

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								article intended for parenteral administration. A single-dose container is labeled as such. Examples of single-dose containers include prefilled syringes, cartridges, fusion-sealed containers, and closure-sealed containers when so labeled.
CYCLOBENZAPRINE HYDROCHLORIDE TABLETS	IMPURITIES/*Organic Impurities/Analysis*	*USP38–NF33*	2972	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 3: Change Calculate the percentage of any individual unspecified degradation product to: Calculate the percentage of any individual degradation product

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND Line 6: Change r_U = peak response of any individual unspecified degradation product from the *Sample solution* to: r_U = peak response of any individual degradation product from the *Sample solution*
LIGHT MINERAL OIL	SPECIFIC TESTS/*Readily Carbonizable Substances Test <271>*	*USP38–NF33*	6763	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 1 of *Acceptance criteria*: Change The *Sample* may turn hazy, but it remains colorless, or shows a slight pink or yellow color, and the *Sample* does not become darker than the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Standard solution. to: The oil portion of the *Sample* may turn hazy, but it remains colorless or shows a slight pink or yellow color, and the acid portion of the *Sample* does not become darker than the *Standard solution*.
POWDERED MILK THISTLE	COMPOSITION /*Content of Silymarin*	*Second Supplement to USP38–NF33*	7880	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 3 of *Sample stock solution*: Change Transfer the thimble to a con tinuous-extraction apparatus fitted with a 250-mL round-bottom flask containing 150 mL of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								hexane, and heat the flask on a heating mantle for 4 h. After the extraction, detach the round-bottom flask from the extraction apparatus, and discard the hexane. Dry the extraction thimble to remove residual hexane, to: Transfer the thimble to a con tinuous-extraction apparatus fitted with a 250-mL round-bottom flask containing 150 mL of solvent hexane, and heat the flask on a heating mantle

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								for 4 h. After the extraction, detach the round-bottom flask from the extraction apparatus, and discard the solvent hexane. Dry the extraction thimble to remove residual solvent hexane,
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE TABLETS	IMPURITIES/*Organic Impurities*	*Second Supplement to USP38–NF33*	8158	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Row 6 of Column 2 of *Table 5*: Change 0.62 to: 0.82
INHALATION AND NASAL DRUG PRODUCTS—AEROSOLS, SPRAYS, AND POWDERS—PERFORMANCE QUALITY TESTS	C. AERODYNAMIC SIZE DISTRIBUTION—INHALATION AEROSOLS, SPRAYS, AND POWDERS	*USP38–NF33*	388	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Line 13 of paragraph 2 of *C.3 Apparatus 2 for Inhalation Powders—Marple Miller Impactor*/*C.3.1 Design—Apparatus 2*: Change Adjust the timer

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								controlling the operation of the two-way solenoid valve so that it opens this valve for a duration of *T* seconds as determined during testing for *Delivered-Dose Uniformity*. to: Adjust the timer controlling the operation of the two-way solenoid valve so that it opens this valve for a duration such that the total volume sampled is at least 4 L. AND Line 3 of paragraph 2 of *C.4 Apparatus 3 for Inhalation P*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								owders—Andersen Impactor (with pre-separator)/*C.4.1 Design—Apparatus 3*: Change Once the product is positioned, discharge the powder into the apparatus by activating the timer and opening the two-way solenoid valve for the required duration, *T* ± 5%, as determined during testing for *Delivered-Dose Uniformity*. to: Once the product is positioned, discharge the powder into the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								apparatus by activating the timer and opening the two-way solenoid valve for the required duration such that the total volume sampled is at least 4 L. AND Line 19 of paragraph 2 of *C.5 Apparatus 4 for Inhalation P owders—Multista ge Liquid Impinger*/*C.5.1 Design—Apparat us 4*: Change Adjust the timer controlling the operation of the two-way solenoid valve so that it opens the valve for the same duration, *T*, as used

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								during testing for *Delivered-Dose Uniformity*. to: Adjust the timer controlling the operation of the two-way solenoid valve so that it opens the valve for the duration such that the total volume sampled is at least 4 L. AND Line 9 of paragraph 4 of *C.6 Apparatus 5 for Inhalation Powders—Next Generation Impactor (with pr e-separator)*/*C.6.2 Procedure—App aratus 5*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Adjust the timer controlling the operation of the two-way solenoid valve so that it opens the valve for the same duration, *T*, as used during testing for *Delivered-Dose Uniformity*. to: Adjust the timer controlling the operation of the two-way solenoid valve so that it opens this valve for a duration such that the total volume sampled is at least 4 L.
OLMESARTAN MEDOXOMIL	IMPURITIES/*Organic Impurities*	*USP38–NF33*	4622	20-Nov-2015	1-Dec-2015	*USP40–NF35*	*Second Supplement to USP39–NF34*	Footnote d of *Impurity Table*: Change (5-Methyl-2-oxo-1,3-dioxol-4-yl)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2?-(2-trityl-1*H*-tetrazol-5-yl)biphenyl-4-yl)methyl)-1*H*-imidazole-5-carboxylate. to: (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2?-(2-trityl-2*H*-tetrazol-5-yl)biphenyl-4-yl)methyl)-1*H*-imidazole-5-carboxylate.
BROMPHENIRAMINE MALEATE	SPECIFIC TESTS/*Optical Rotation, Specific Rotation <781>*	*USP38–NF33*	2475	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 1: Delete *Specific Rotation* AND Line 1 of *Sample*: Change 100 mg/mL in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								water to: 100 mg/mL in water at 20°
IPRATROPIUM BROMIDE	DEFINITION	*USP38–NF33*	3932	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 2: Change ($C_{20}H_{30}BrNO_3 \cdot H_2O$) to: ($C_{20}H_{30}BrNO_3$)
OXAZEPAM	SPECIFIC TESTS/*pH <791>*	*USP38–NF33*	4683	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 1: Change *Sample solution*: 20 mg/mL to: *Sample*: A suspension of 1 g of Oxazepam in 50 mL water
RIVASTIGMINE TARTRATE	IMPURITIES/*Organic Impurities/Procedure 1*	*USP38–NF33*	5213	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Footnote c of *Impurity Table 1*: Change (*S*)-3-[1-(Dimethylamino)ethyl]phenyl dimethylcarbamate (rivastigmine related compound B). to: (*S*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								)?3?[1?(Dimethylamino)ethyl]phenyl dimethylcarbamate (racemic mixture is rivastigmine related compound B).
SODIUM STEARYL FUMARATE	SPECIFIC TESTS/*Fats and Oils, Saponification Value <401>*	*USP38–NF33*	6877	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 6 of *Analysis*: Change Rinse the condenser with two 10-mL portions of 70% alcohol, add phenolphthalein TS, to: Rinse the condenser with 10 mL of 70% alcohol, followed by three 10-mL portions of water, collecting the rinsings in the flask. Cool, rinse the sides

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								of the flask with two 10-mL portions of 70% alcohol, add phenolphthalein TS,
ANTIBIOTICS—MICROBIAL ASSAYS	APPENDIX 1. FORMULAS FOR MANUAL CALCULATIONS OF REGRESSION AND SAMPLE CONCENTRATION	*USP38–NF33*	133	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 19: Change b = [(4 × 17.222) + (2 × 16.511) ? (2 × 14.989) ? (4 × 14.020)]/{5[ln(7.81)] ? ln(3.2)} = 3.551 to: b = [(4 × 17.222) + (2 × 16.511) ? (2 × 14.989) ? (4 × 14.020)]/{5[ln(7.81) ? ln(3.2)]} = 3.551
ETHOTOIN	*Related compounds/ Procedure*	*USP38–NF33*	3415	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 11:Change weight, in mg, on the anhydrous basis, of the portion of Ethotoin taken; to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								weight, in mg, of the portion of Ethotoin taken;
NALOXONE HYDROCHLORIDE	IMPURITIES/ *Noroxymorphone Hydrochloride [(?)-4,5?-Epoxy-3,14-Dihydroxymorphinan-6-one-hydrochloride] and Other Impurities/ Chromatographic system*	*USP38–NF33*	4486	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Add *Application volume*: 5 µL
RIVASTIGMINE	IMPURITIES/*Organic Impurities*	*USP38–NF33*	5212	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Row 3 of Column 1 of *Table 1*: Change Nor impurity (rivastigmine related compound B) to: Nor impurity[a] AND Add footnote a: [a](*S*)?3?[1?(Dimethy

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								lamino)ethyl]phenyl dimethylcarbamate (racemic mixture is rivastigmine related compound B).
ROPIVACAINE HYDROCHLORIDE INJECTION	*USP Reference standards <11>*	*USP38–NF33*	5227	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 2 of USP Ropivacaine Related Compound B RS: Change (*R*)-ropivacaine hydrochloride monohydrate; (*R*)-(?)-1-propylpiperidine-2-carboxylic acid (2,6-dimethylphenyl)-amide hydrochloride monohydrate. to: (*R*)-Ropivacaine hydrochloride monohydrate; (*R*)-(+)-1-propylpip

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								eridine-2-carboxylic acid (2,6-dimethylphenyl)-amide hydrochloride monohydrate.
CALCIUM LACTATE TABLETS	ASSAY/ *Procedure*	*USP38–NF33*	2553	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 3 of *Analysis*: Change While stirring, add 30 mL of *Titrant* from a 50-mL buret. to: While stirring, add 15 mL of *Titrant* from a 50-mL buret.
IPRATROPIUM BROMIDE	ASSAY/ *Procedure*	*USP38–NF33*	3932	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 4 of *Analysis*: Change ($C_{20}H_{30}BrNO_3 \cdot H_2O$) to: ($C_{20}H_{30}BrNO_3$)
RIBAVIRIN TABLETS	IM PURITIES/*Organic Impurities, Procedure 1*	*USP38–NF33*	5162	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Footnote e of *Table 2*: Change 1-?-D-Ribofuranosyl-1*H*-1,2,4-triazole-3

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-carboxamide. to: 1-?-D-Ribofuranosyl-1*H*-1,2,4-triazole-5-carboxamide.
RIVASTIGMINE TARTRATE CAPSULES	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP38–NF33*	5215	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 2 of USP Rivastigmine Related Compound B RS: Change *N*,*N*-Dimethylcarbamic acid-3-[1-(dimethylamino)ethyl]phenyl ester. to: (*RS*)?3?[1?(Dimethylamino)ethyl]phenyl dimethylcarbamate.
CHLORPHENIRAMINE MALEATE	SPECIFIC TESTS/*Optical Rotation, Specific Rotation <781>*	*Second Supplement to USP38–NF33*	Online	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 1: Delete *Specific Rotation*
BOVINE SERUM	APPENDIX 1	*USP38–NF33*	719	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 2 of bullet 1 of International

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Regulations and Guidance Documents in second paragraph: Change http://www.emea.europa.eu/pdfs/human/bwp/026895en.pdf to: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003684.pdf AND Line 2 of bullet 2 of International Regulations and Guidance Documents in second paragraph: Change http://www.emea.europa.eu/pdf

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								s/human/bwp/179302en.pdf to: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/WC500003675.pdf AND Line 3 of bullet 3 of International Regulations and Guidance Documents in second paragraph: Change http://www.emea.europa.eu/pdfs/vet/iwp/074300en.pdf to: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC50000

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								4575.pdf AND Delete bullet 4 of International Regulations and Guidance Documents in second paragraph AND Line 2 of bullet 5 of International Regulations and Guidance Documents in second paragraph: Change http://www.emea.europa.eu/pdfs/human/bwp/TSE%20NFG%20410-rev2.pdf to: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC50000

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								3712.pdf AND Line 1 of bullet 6 of International Regulations and Guidance Documents in second paragraph: Change Terrestrial animal health code 2007. Available at http://www.oie.int/eng/normes/mcode/code2007/anc-en_summary.htm. to: Terrestrial animal health code. Available at http://www.oie.int/doc/ged/D10905.pdf.
HYDROXYZINE PAMOATE ORAL	ADDITIONAL REQUIREMENTS/*USP*	*USP38–NF33*	3817	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Delete USP Hydroxyzine

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SUSPENSION	*Reference Standards <11>*							Hydrochloride RS
NOREPINEPHRINE BITARTRATE	CHEMICAL INFORMATION	*USP38–NF33*	4582	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 6: Change [69815-49-2]. to: [108341-18-0].
RIVASTIGMINE TARTRATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP38–NF33*	5213	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 2 of USP Rivastigmine Related Compound B RS: Change *N*,*N* -Dimethylcarbamic acid-3-[1-(dimethylamino)ethyl]phenyl ester. to: (*RS*)?3?[1?(Dimethylamino)ethyl]phenyl dimethylcarbamate.
VALGANCICLOVIR HYDROCHLORIDE	*Assay*	*USP38–NF33*	5729	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 4 of *Procedure*: Change Calculate the percentage, on the anhydrous and solvent-free basis, of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$C_{14}H_{22}N_6O_5$ · HCl to: Calculate the percentage of valganciclovir hydrochloride ($C_{14}H_{22}N_6O_5$ · HCl) AND Line 8 of *Procedure*: Change $100[(r_U / W_U)(C_F)(100) /(100 ? S_U)]$ to: $100[(r_U/W_U)(C_F)(100)]$ AND Line 12 of *Procedure*: Change C_F is the correction factor; and S_U is the total percent of solvent and water in the test sample. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and C_F is the correction factor. AND Line 16 of *Procedure*: Change (W_S / R_S)[(100 ? S_S) /100] to: (W_S/R_S)/100 AND Line 18 of *Procedure*: Change R_S is the area response (sum of two peaks for valganciclovir diastereomers) obtained from the *Standard preparation*; and S_S is the total percent of solvent and water in USP Valganciclovir Hydrochloride RS. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and R_S is the area response (sum of two peaks for valganciclovir diastereomers) obtained from the *Standard preparation*.
MUCOSAL DRUG PRODUCTS—PRODUCT QUALITY TESTS	PRODUCT QUALITY TESTS FOR MUCOSAL DRUG PRODUCTS /*General Necessary Tests*/*Impurities*	*USP38–NF33*	76	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 1 of footnote 2: Change http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3B_R2/Step4/Q3B_R2_Guideline.pdf. to: http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html.
CHLOROXYLENOL	IMPURITIES/*Limit of Tetrachloroethylene*	*USP38–NF33*	2774	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Row 3 of Column 1 of *Table 2*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								210 to: 70 Row 3 of Column 2 of *Table 2*: Change 0 to: 35
METHOHEXITAL	CHEMICAL INFORMATION	*USP38–NF33*	4316	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 5: Change [18652-93-2] to: [151-83-7]
RIVASTIGMINE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP38–NF33*	5212	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 2 of USP Rivastigmine Related Compound B RS: Change Nor impurity; (*S*)-3-[1-(Dimethylamino)ethyl]phenyl dimethylcarbamate. to: Nor impurity (racemic mixture); (*RS*)?3?[1?(Dimethy

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								lamino)ethyl]phenyl dimethylcarbamate.
ROPIVACAINE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP38–NF33*	5225	25-Sep-2015	1-Oct-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 2 of USP Ropivacaine Related Compound B RS: Change (*R*)-ropivacaine hydrochloride monohydrate; (*R*)-(?)-1-propylpiperidine-2-carboxylic acid (2,6-dimethylphenyl)-amide hydrochloride monohydrate. to: (*R*)-Ropivacaine hydrochloride monohydrate; (*R*)-(+)-1-propylpiperidine-2-carboxylic acid (2,6-dimethylphenyl)-amide hydrochloride

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								monohydrate.
OXAPROZIN TABLETS	IMPURITIES/*Organic Impurities*/*System suitability*/*Suitability requirements*	*USP38–NF33*	4681	31-Jul-2015	1-Aug-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Delete the subsection *Signal-to-noise ratio:* NLT 3000
METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER	DEFINITION	*USP38–NF33*	6753	31-Jul-2015	1-Aug-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 4: Change Methacrylic acid units in Methacrylic Acid and Ethyl Acrylate Copolymer are NLT 46.0% and NMT 50.6%, calculated on the dried basis. to: Methacrylic acid units in Methacrylic Acid and Ethyl Acrylate Copolymer, previously dried, are NLT 46.0% and NMT 50.6%.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ALMOTRIPTAN MALATE	IM PURITIES/*Limit of Almotriptan Related Compound D and Almotriptan N-Dimer*	*First Supplement to USP38–NF33*	7325	31-Jul-2015	1-Aug-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 1of *Internal standard solution*: Change 4-hydroxy-phenylpiperidine to: 4-hydroxy-4-phenylpiperidine
METHOTREXATE	IM PURITIES/*Organic Impurities/Procedure 1: Related Compounds*	*USP38–NF33*	4318	31-Jul-2015	1-Aug-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 15 of *Analysis*: Change methotrexate related compound E free acid to: methotrexate related compound E free base AND Line 8 of the second variable definition list for *Analysis*: Change methotrexate related compound E free acid

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: methotrexate related compound E free base AND Row 5 of Column 1 of *Impurity Table 1*: Change Methotrexate related compound E free acid[c] to: Methotrexate related compound E free base[c]
TETRACAINE HYDROCHLORIDE FOR INJECTION	*Chromatographic purity*	*USP38–NF33*	5508	31-Jul-2015	1-Aug-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 1: Change Dissolve an accurately weighed quantity of *Tetracaine Hydrochloride for Injection* in water to obtain a test solution containing 50 mg per mL, and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								proceed as directed in the test for *Chromatographic purity* under *Tetracaine*, beginning with “Prepare a Standard solution.” to: Dissolve an accurately weighed quantity of Tetracaine Hydrochloride for Injection in water to obtain a test solution containing 50 mg per mL. Prepare a Standard solution of 4-(butylamino) benzoic acid in methanol containing 0.2 mg per mL. Apply separate

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								5-µL portions of the test solution and the Standard solution to a suitable thin-layer chromatographic plate (see *Chromatography <621>*) coated with a 0.25-mm layer of chromatographic silica gel mixture. Develop the plate in a suitable chromatographic chamber containing a solvent system consisting of a mixture of chloroform, methanol, and isopropylamine (98:7:2) until the solvent front has moved about three-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								fourths of the length of the plate. Remove the plate from the chamber, and dry in a current of warm air. Examine the plate under shor t-wavelength UV light: any spot obtained from the test solution, other than the principal spot, is not more intense than the principal spot obtained from the Standard solution (0.4%), and the sum of the intensities of any such spots is not greater than 0.8%.
METHACRYLIC ACID AND METHYL METH ACRYLATE	ASSAY/ *Procedure*	*USP38–NF33*	6755	31-Jul-2015	1-Aug-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	Line 3 of *Acceptance criteria*: Delete on the dried

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
COPOLYMER								basis AND Line 5 of *Acceptance criteria*: Delete on the dried basis
BIOTECHNOLOGY-DERIVED ARTICLES -- POLYACRYLAMIDE GEL ELECTROPHORESIS	INTRODUCTION	*Harmonization (Official December 01, 2015)*	Online	31-Jul-2015	1-Aug-2015	*USP40–NF35*	*First Supplement to USP39–NF34*	A paragraph before the *Introduction* was deleted: This chapter provides guidance and procedures used for characterization of biotechnology-derived articles by polyacrylamide gel electrophoresis. Portions of the chapter that are not harmonized with the other two pharmacopeias are marked by the symbol ?.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								This chapter is harmonized with the corresponding chapter in *JP* and *EP*. Other characterization tests, also harmonized, are shown in *Biotechnology-Derived Articles—Amino Acid Analysis <1052>*, *Biotechnology-Derived Articles—Capillary Electrophoresis <1053>*, *Biotechnology-Derived Articles—Isoelectric Focusing <1054>*, *Biotechnology-Derived Articles—Peptide Mapping <1055>*, and *Biotechnology-*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Derived Articles—Total Protein Assay <1057>.

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 15
- Page 16
- Page 17
- Page 18
- Page 19
- Page 20
- Page 21
- Page 22
- Page 23
- …
- Next page Next ›
- Last page Last »